Virus filtration is a crucial step in the production of various biologics including vaccines and monoclonal antibodies to remove viral contaminations. It ensures product safety and purity. Virus filtration products are used across upstream and downstream bioprocessing applications. The technologies used for virus filtration include membrane filter, filtration systems, and services. It aids in elimination of small viruses and virus-like particles from liquid samples without disrupting the product quality. The technologies exploit size-based separation and are capable of removing viruses as small as 15-25 nanometers from solution.
The global Virus Filtration Market is estimated to be valued at Us$ 5.86 Mn in 2023 and is expected to exhibit a CAGR Of 3.1% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Increasing research activities in cell and gene therapy coupled with growing adoption of single-use technologies is expected to drive the growth of virus filtration market over the forecast period. Gene and cell therapies are complex living drug products facing regulatory challenges pertaining to product safety and purity. Virus filtration plays a critical role in validating the viral clearance ability of such novel therapies. This is augmenting the demand for virus filtration products amongst biopharmaceutical companies. In addition, continuous technological advancements to enhance virus removal capabilities are further fuelling the market growth. For instance, development of monolithic adsorbers having large surface area for virus binding is gaining traction. However, high capital requirement for virus filtration equipment might hamper the market growth in the initial years.
SWOT Analysis
Strength: The virus filtration market has seen steady growth in recent years owing to rising R&D activities in the biopharmaceutical industry. The growing demand for monoclonal antibodies and recombinant proteins has increased the focus on virus clearance during drug development and manufacturing processes. Stringent regulatory guidelines regarding viral safety of biologics and vaccines have further propelled the adoption of virus filtration systems.
Weakness: High capital investment requirements for virus filtration systems pose financial challenges to new and small players. The need for specialized technical expertise to operate these advanced filtration systems may also limit their widespread adoption.
Opportunity: Emerging economies in Asia Pacific and Latin America are expected to offer lucrative opportunities for market expansion as their biopharma industries are growing. In addition, increasing plasmid DNA therapies and gene therapy research will augment the need for effective viral clearance solutions during manufacturing.
Threats: Differing regulations across regions regarding viral validation add an element of uncertainty. Economic slowdowns may constrain biopharma spending on downstream processing equipment. Intense competition among established players can also influence pricing and profitability.
Key Takeaways
The Global Virus Filtration Market Demand is expected to witness high growth over the forecast period driven by increasing demand for biotherapeutics and vaccines. The market size is estimated to reach US$ 5.86 million in 2024 and is projected to surpass US$ 7.1 million in value by 2031, registering a CAGR of 3.1% during the forecast period. Stringent regulations ensure high demand for virus clearance in bioproduction.
Regional analysis indicates that North America currently dominates the market owing to presence of major players and significant biopharma manufacturing activity in the US and Canada. Asia Pacific is poised to be the fastest growing regional market attributed to rising biotech investments and expanding biosimilar production capacity in China, India, and South Korea.
Key players operating in the virus filtration market are Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Merck KGaA. Asia Pacific region offers lucrative opportunities for market expansion as biopharmaceutical industries in China, India and South Korea are witnessing rapid growth. Stringent quality standards are driving widespread adoption of virus filtration systems across emerging biotech clusters in the region.
Get more insights on this topic :
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian